Saturday 17 October 2026
Export NNOX’s income statement to Excel — free account
Nano-X Imaging Ltd.
NNOX Healthcare Medical Devices
Nano-X Imaging Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 15.4% from fiscal 2024. In the quarter to June 2026, revenue grew 36.7%, EPS fell 243.5%, free cash flow fell 21.4% and total debt fell 12.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
0.45
0.04
−8.16%
Follow NNOX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
19.35 | 13.93 | 10.89 | 5.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.16) | (17.42) | (11.33) | (7.00) | |
P/B ratio |
1.52 | 1.30 | 1.25 | 1.12 | |
Price to Tangible BV |
2.51 | 2.28 | 2.30 | 1.40 | |
EV/Sales |
16.21 | 10.66 | 8.30 | 3.61 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.87) | (3.40) | (2.71) | (1.21) | |
EV/FCF |
(4.40) | (3.08) | (2.42) | (1.08) | |
Quick Ratio |
3.80 | 3.03 | 3.26 | 2.40 | |
Current Ratio |
4.14 | 3.96 | 3.64 | 2.84 | |
Net Debt/EBITDA |
3.74 | 1.41 | 3.48 | 0.53 | |
Debt/Assets |
1.82% | 1.93% | 2.04% | 3.20% | |
Debt/Equity |
0.02 | 0.02 | 0.02 | 0.04 | |
Asset Turnover |
0.07 | 0.07 | 0.08 | 0.11 | |
Operating CF/Net income |
0.78 | 0.31 | 0.98 | 0.21 | |
Capex/Depreciation |
(0.58) | (0.31) | (0.63) | (0.35) | |
Research and Development Expense of Revenue |
133.04% | 130.09% | 111.30% | 113.26% | |
Selling, General and Administrative Expense of Revenue |
196.23% | 216.32% | 171.75% | 176.71% | |
Intangible Assets out of Total Assets |
0.35 | 0.37 | 0.40 | 0.16 | |
Share Based Compensation of Revenue |
31.88% | 21.89% | 19.51% | 20.91% | |
Graham Net Nets |
0.13 | 0.24 | 0.20 | 0.25 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(23.86%) | (41.17%) | (50.34%) | (146.78%) | |
Free Cash Flow Yield |
(19.02%) | (24.81%) | (31.56%) | (64.22%) | |
Revenue per Share |
0.05 | 0.06 | 0.06 | 0.06 | |
Operating CF per Share |
(0.17) | (0.16) | (0.20) | (0.17) | |
Capex per Share |
(0.03) | (0.01) | (0.03) | (0.01) | |
Free Cash Flow per Share |
(0.19) | (0.17) | (0.23) | (0.18) | |
Cash per Share |
0.70 | 0.76 | 0.63 | 0.44 | |
Shareholders Equity per Share |
2.44 | 2.16 | 1.81 | 1.04 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.44 | 2.16 | 1.81 | 1.04 | |
Free Cash Flow |
(12.48) | (11.30) | (15.73) | (12.58) | |
Working Capital |
38.92 | 49.91 | 37.21 | 25.27 | |
Capital Expenditures |
(1.74) | (0.89) | (1.78) | (0.98) | |
Net Current Asset Value |
31.94 | 44.36 | 31.87 | 20.27 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.50 | 0.24 | 0.41 | 0.24 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.71 | 1.91 | 1.97 | 1.88 | |
Average Payables |
1.37 | 2.55 | 2.17 | 2.21 | |
Average Inventory |
1.85 | 2.28 | 2.51 | 2.83 | |
Average Assets |
180.01 | 186.08 | 171.25 | 137.71 | |
Average Common Equity |
160.30 | 164.43 | 151.74 | 118.01 |
Columns are period end dates